Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Extension Study of Recifercept in Children With Achondroplasia
2021-003149-39Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Sep 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recifercept in achondroplasia (ACH), sponsored by Pfizer. Primary endpoints: Long-term safety and tolerability of recifercept, Pharmacokinetics of recifercept and 1 more. Started Sep 2021; status: terminated.
02
Drugs
recifercept
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2021-003149-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003149-39.